Anti-IL-23 Antibodies, Compositions, Methods and Uses

Patent metadata

Field	Value
Publication number	US-2017290912-A1
Application number	US-201715626697-A
Country	US
Kind code	A1
Filing date	Jun 19, 2017
Priority date	Jun 30, 2005
Publication date	Oct 12, 2017
Grant date	—

Abstract

An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

First claim

What is claimed is:

1 . An isolated IL-23p19 antibody fragment, comprising a light chain variable region comprising:
a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:29; a CDRL2 amino acid sequence of SEQ ID NO:30; and a CDRL3 amino acid sequence of SEQ ID NO:31, and/or a heavy chain variable region comprising: a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:24; a CDRH2 amino acid sequence of SEQ ID NO:25; and a CDRH3 amino acid sequence of SEQ ID NO:26.

2 . The isolated IL-23p19 antibody fragment of claim 1 , comprising a light chain variable region amino acid sequence of SEQ ID NO:28.

3 . The isolated IL-23p19 antibody fragment of claim 1 , comprising a heavy chain variable region amino acid sequence of SEQ ID NO:23.

4 . The isolated IL-23p19 antibody fragment of claim 1 , wherein said antibody light chain variable region is at least one of chimerized, humanized, and CDR-grafted.

5 . A composition comprising the isolated IL-23p19 antibody fragment of claim 1 , and at least one pharmaceutically acceptable carrier or diluent.

6 . The composition of claim 5 , further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist.

7 . The isolated IL-23p19 antibody fragment of claim 1 , wherein said fragment is selected from the group consisting of a Fab, Fab′, F(ab′) 2 , pFc, Fd, Fv, scFv, and fragments thereof.

8 . An antibody that competitively binds to IL-23p19 with the isolated IL-23p19 antibody fragment of claim 1 .

9 . The isolated IL-23p19 antibody fragment of claim 1 , wherein said antibody fragment binds IL-23p19 with at least one affinity selected from at least 10 −9 M, at least 10 −10 M, at least 10 −11 M, and at least 10 −12 M, at least 10 −13 M, at least 10 −14 M, and at least 10 −15 M, as determined by surface plasmon resonance or the Kinexa method.

10 . The isolated IL-23p19 antibody fragment of claim 1 , wherein said antibody fragment binds IL-23p19 with an affinity between about 3.38×10 −10 M and about 4.3×10 −11 M, as determined by surface plasmon resonance.

11 . The isolated IL-23-p19 antibody fragment of claim 1 , wherein said antibody fragment downregulates an activity of the IL-23 polypeptide comprising SEQ ID NO:1, the activity being selected from the group consisting of binding to the IL-23 receptor (IL-23R), induction of STAT3 phosphorylation, and IL-17 production.

Assignees

• Janssen Biotech Inc

Inventors

• Benson Jacqueline
• Cunningham Mark
• Duchala Cynthia
• Giles-Komar Jill
• Luo Jinquan
• Rycyzyn Michael
• Sweet Raymond

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P27/02

  Ophthalmic agents · CPC title